Acute promyelocytic leukemia after mitoxantrone therapy for multiple sclerosis

Abstract Mitoxantrone is a DNA-topoisomerase 2 inhibitor used as a single agent for treatment of relapsing–remitting or progressive multiple sclerosis (MS). We present here two patients treated with mitoxantrone for MS who subsequently developed acute promyelocytic leukemia (APL). These constitute,...

Full description

Saved in:
Bibliographic Details
Published in:Cancer genetics and cytogenetics 2008-04, Vol.182 (2), p.126-129
Main Authors: Ramkumar, Bhuvaneswari, Chadha, Manpreet K, Barcos, Maurice, Sait, Sheila N.J, Heyman, Meyer R, Baer, Maria R
Format: Article
Language:English
Subjects:
Antineoplastic Agents - adverse effects
Chromosomes, Human, Pair 11 - genetics
Female
Hematology, Oncology and Palliative Medicine
Humans
In Situ Hybridization, Fluorescence
Karyotyping
Leukemia, Promyelocytic, Acute - chemically induced
Leukemia, Promyelocytic, Acute - drug therapy
Male
Medical Education
Middle Aged
Mitoxantrone - adverse effects
Multiple Sclerosis - drug therapy
Remission Induction
Translocation, Genetic
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Mitoxantrone is a DNA-topoisomerase 2 inhibitor used as a single agent for treatment of relapsing–remitting or progressive multiple sclerosis (MS). We present here two patients treated with mitoxantrone for MS who subsequently developed acute promyelocytic leukemia (APL). These constitute, to our knowledge, the eighth and ninth reports of APL in patients treated with mitoxantrone for MS. Topoisomerase 2 inhibitors are associated with therapy-related acute myeloid leukemia (t-AML) with 11q23 abnormalities, but therapy-related APL (t-APL) is less common, and documentation of nine cases of t-APL after mitoxantrone therapy for MS suggests a specific association.
ISSN:0165-4608
1873-4456
DOI:10.1016/j.cancergencyto.2008.01.004